Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
ATTRACT: internationaal onderzoek naar nieuwe middelen zeldzame kankers
feb 2024 | Bot en wekedelentumoren, Leukemie